CytoMed Therapeutics (GDTC) Interest Expenses (2023 - 2025)
CytoMed Therapeutics (GDTC) posted Interest Expenses of $8639.0 for Q2 2024, down 64.55% sequentially from $24370.0 in Q2 2023, and down 64.55% YoY from $24370.0 in Q3 2023.
CytoMed Therapeutics (GDTC) Interest Expenses (2023 - 2025) Analysis & Trends
CytoMed Therapeutics has reported Interest Expenses for 2 years, with the latest figure at $8639.0 in Q2 2024.
- Quarterly Interest Expenses fell 64.55% year-over-year to $8639.0 in Q2 2024, while the trailing twelve-month figure through Dec 2025 was $8639.0 (down 73.83% YoY) and the FY2025 annual result came in at $16258.0, up 9.35% from the prior year.
- Interest Expenses fell to $8639.0 in Q2 2024 per GDTC's latest filing, from $24370.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $24370.0 in Q2 2023 and troughed at $8639.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | CytoMed Therapeutics | 10.72 Mn | 9.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 10,310.00 |
| Jun 30, 2025 | 10,310.00 |
| Jun 30, 2024 | 8,639.00 |
| Jun 30, 2024 | 8,639.00 |
| Jun 30, 2023 | 24,370.00 |
| Jun 30, 2023 | 24,370.00 |